Pamela Coxson, PhD


Pamela Coxson, PhD is a mathematician with the Division of General and Internal Medicine and member of the CVP Cardiovascular Disease Modelling Group. She is responsible for design and maintenance of the CHD Policy Model, implementation of analyses using the Model, and interpretation of Model data. Current projects include adaptation of the Model to assess the CHD burden and benefits of treatment in vulnerable populations. Dr. Coxson received her Ph.D. in mathematics from the University of Southern California.

  1. Projected impact of a reduction in sugar-sweetened beverage consumption on diabetes and cardiovascular disease in Argentina: A modeling study.
  2. Cardiovascular and diabetes burden attributable to physical inactivity in Mexico.
  3. Association of Low Socioeconomic Status With Premature Coronary Heart Disease in US Adults.
  4. The Cardiovascular Health Burdens of Solitary Confinement.
  5. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
  6. Update of the cardiovascular disease policy model to predict cardiovascular events in Argentina.
  7. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
  8. Potential Cardiovascular and Total Mortality Benefits of Air Pollution Control in Urban China.
  9. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
  10. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
  11. Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina.
  12. Projected Impact of Mexico's Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study.
  13. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
  14. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
  15. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
  16. Gait Speed as a Guide for Blood Pressure Targets in Older Adults: A Modeling Study.
  17. Projected Impact of Salt Restriction on Prevention of Cardiovascular Disease in China: A Modeling Study.
  18. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
  19. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States.
  20. Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model.
  21. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
  22. Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
  23. Health benefits of reducing sugar-sweetened beverage intake in high risk populations of California: results from the cardiovascular disease (CVD) policy model.
  24. Projected impact of a sodium consumption reduction initiative in Argentina: an analysis from the CVD policy model--Argentina.
  25. Response to mortality benefits from U.S. population-wide reduction in sodium consumption: projections from 3 modeling approaches.
  26. Mortality benefits from US population-wide reduction in sodium consumption: projections from 3 modeling approaches.
  27. Impact on cardiovascular disease events of the implementation of Argentina's national tobacco control law.
  28. [The cost-utility ratio of reducing salt intake and its impact on the incidence of cardiovascular disease in Argentina].
  29. Projected impact of urbanization on cardiovascular disease in China.
  30. A penny-per-ounce tax on sugar-sweetened beverages would cut health and cost burdens of diabetes.
  31. Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.
  32. The impact of the aging population on coronary heart disease in the United States.
  33. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
  34. Coronary heart disease and stroke attributable to major risk factors is similar in Argentina and the United States: the Coronary Heart Disease Policy Model.
  35. Effectiveness of a barber-based intervention for improving hypertension control in black men: the BARBER-1 study: a cluster randomized trial.
  36. Does age modify effectiveness of statin therapy in coronary artery disease?
  37. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china.
  38. Projected effect of dietary salt reductions on future cardiovascular disease.
  39. Forecasting the future economic burden of current adolescent overweight: an estimate of the coronary heart disease policy model.
  40. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
  41. Coronary heart disease attributable to passive smoking: CHD Policy Model.
  42. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China.
  43. Adolescent overweight and future adult coronary heart disease.
  44. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.